ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria
Gema Ariceta(Hospital de Cruces), Gesa Schalk, Bastian Dehmel(Amgen (Switzerland)), Tracy E. Hunley(Vanderbilt University), Gloria Fraga(Hospital de Sant Pau), Laure Collard(Centre Hospitalier Chrétien), Ana Baños(OxThera (Sweden)), Abir Boussetta(Hôpital Charles-Nicolle), Sudarsana De(Rabindranath Tagore International Institute of Cardiac Sciences), F. Jarraya(University of Sfax), Edward Gould(Vanderbilt University), M. Ben Hmida(Hopital Universitaire Hedi Chaker), Shabbir H. Moochhala(Université Claude Bernard Lyon 1), Elisabeth Lindner(OxThera (Sweden)), Saoussen Abroug(Hôpital Sahloul)
Cited by 21
Related Papers
Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities
|Nature|2012|631
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|509
The MEST score provides earlier risk prediction in lgA nephropathy
|Kidney International|2015|297
Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*
|Nephrology Dialysis Transplantation|2017|228
The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary
|Clinical Kidney Journal|2017|212